Literature DB >> 11919429

Treatment of cutaneous mastocytosis.

Klaus Wolff1.   

Abstract

Therapy of cutaneous mastocytosis is directed towards skin and systemic symptoms due to mediator release and targeted on skin lesions. Symptomatic therapy of cutaneous mastocytosis involves agents that inhibit the release of mediators or antagonize H1 and H2 receptors such as antihistamines ketodifen and Aspirin. Disodium cromoglycate has no effect of the cutaneous symptoms of cutaneous mastocytosis. Skin-targeted therapies that lead to a resolution of the lesions of cutaneous mastocytosis are psoralen-photochemotherapy and topical corticosteroid therapy either by occlusion or intralesional injection for a limited number of lesions. There is no treatment that permanently cures cutaneous mastocytosis and patient selection will therefore have to be made on the basis of the clinical manifestations, onset of disease, the probability of spontaneous involution and the severity of cutaneous and systemic symptoms. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11919429     DOI: 10.1159/000048190

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

Authors:  V Schleyer; S Meyer; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

Review 2.  Primary mast cell disorders in children.

Authors:  Ari J Fried; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

Review 3.  Contemporary challenges in mastocytosis.

Authors:  H David Pettigrew; Suzanne S Teuber; James S Kong; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 4.  The problem of anaphylaxis and mastocytosis.

Authors:  Ulrich R Müller; Gabrielle Haeberli
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

5.  Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis.

Authors:  Iris M Otani; Ryan W Carroll; Phoebe Yager; Daniela Kroshinsky; Sarah Murphy; Jason L Hornick; Cem Akin; Mariana Castells; Jolan E Walter
Journal:  Clin Case Rep       Date:  2018-07-31

6.  Mastocytosis in children and adults: clinical disease heterogeneity.

Authors:  Magdalena Lange; Bogusław Nedoszytko; Aleksandra Górska; Anton Zawrocki; Michał Sobjanek; Dariusz Kozlowski
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

7.  Molecular Mechanisms of UV-Induced Apoptosis and Its Effects on Skin Residential Cells: The Implication in UV-Based Phototherapy.

Authors:  Chih-Hung Lee; Shi-Bei Wu; Chien-Hui Hong; Hsin-Su Yu; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2013-03-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.